Insider sales and context
Solomon Moshkevich, who serves as President, Clinical Diagnostics at Natera, Inc. (NASDAQ: NTRA), sold a combined 2,213 shares of common stock in two separate transactions that produced about $528,853 in proceeds. The share prices for the two dispositions ranged from $237.6624 to $240.5313, modestly higher than the cited current trading price of $231.48.
The first transaction took place on January 27, 2026, when Moshkevich sold 1,013 shares at $240.5313 per share. After that sale he directly held 143,686 shares of the company. The second trade occurred on January 28, 2026, when he sold 1,200 shares at $237.6624 per share, leaving him with 142,486 directly owned shares.
Moshkevich's sales were disclosed as being executed to satisfy tax liabilities that arose from the vesting of Restricted Stock Units. The trades were carried out pursuant to a pre-arranged trading plan designed to comply with Rule 10b5-1(c), the mechanism frequently used by insiders to establish scheduled dispositions without active timing decisions.
Valuation and financial signals
InvestingPro analysis referenced alongside the transaction data indicates that Natera, with a reported market capitalization of $31.95 billion, appears overvalued relative to its Fair Value estimate. At the same time, InvestingPro assigns Natera a "GOOD" overall financial health score and offers a Pro Research Report on the company.
Operational and clinical updates cited
Alongside the insider activity, the company reported encouraging preliminary fourth-quarter results, estimating revenue growth of nearly 40% year-over-year and a 17% rise in test volume. In response to those metrics, Canaccord Genuity maintained a Buy rating on Natera with a $285.00 price target.
Natera also announced a sequence of clinical and product developments: it has completed enrollment for the ACES-EMB trial, which is designed to evaluate whether the Prospera Heart test can substitute for invasive biopsies in heart transplant monitoring. In oncology, Natera will participate with Exelixis in the STELLAR-316 trial for colorectal cancer, deploying its Signatera assay to identify patients with molecular residual disease.
Further product advances noted include a new AI model intended to integrate multiple data sources to refine cancer recurrence risk assessment for the Signatera MRD test, and planned presentation of EXPAND trial data on fetal genetic screening at the Society for Maternal-Fetal Medicine meeting. Collectively these items underscore ongoing efforts to advance Natera's testing technologies across cardiovascular, oncology, and fetal medicine applications.
What the transactions mean
The insider sales were explicitly tied to tax withholding obligations from RSU vesting rather than described as discretionary monetization of shares. Even after the two trades, Moshkevich retains a substantial direct equity stake in the company. The market-capitalization and InvestingPro Fair Value note signal analysts may view the shares as carrying an elevated valuation relative to intrinsic assessments, while the company's operational updates point to potential clinical and commercial catalysts.